[
    {"6MWT": "6-minute walk test"},
    {"99mTc-PYP": "Technetium-labelled pyrophosphate"},
    {"AATAC": "Ablation vs. Amiodarone for Treatment of Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted ICD/CRTD (trial)"},
    {"AC": "Arrhythmogenic cardiomyopathy"},
    {"ACE": "Angiotensin-converting enzyme"},
    {"ACE-I": "Angiotensin-converting enzyme inhibitor"},
    {"ACHD": "Adult congenital heart disease"},
    {"ACS": "Acute coronary syndrome"},
    {"ADHF": "Acutely decompensated heart failure"},
    {"AF": "Atrial fibrillation"},
    {"AF-CHF": "Atrial fibrillation Congestive Heart Failure (trial)"},
    {"AFFIRM": "Atrial Fibrillation Follow-up Investigation of Rhythm Management (trial)"},
    {"AFFIRM-AHF": "A Randomized, Double-blind Placebo-controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalizations and Mortality in Iron-deficient Subjects Admitted for Acute Heart Failure (trial)"},
    {"AHF": "Acute heart failure"},
    {"AL": "Light chain immunoglobulin"},
    {"AL-CA": "Light chain immunoglobulin cardiac amyloidosis"},
    {"AMICA": "Atrial Fibrillation Management in Congestive Heart Failure With Ablation (trial)"},
    {"ANCA": "Antineutrophil cytoplasmic antibody"},
    {"ARB": "Angiotensin-receptor blocker"},
    {"ARNI": "Angiotensin receptor-neprilysin inhibitor"},
    {"ARVC": "Arrhythmogenic right ventricular cardiomyopathy"},
    {"ATTR": "Transthyretin amyloidosis"},
    {"AV": "Atrio-ventricular"},
    {"b.i.d.": "Bis in die (twice daily)"},
    {"BAG3": "Bcl2-associated athanogene 3"},
    {"BiVAD": "Biventricular assist device"},
    {"BMI": "Body mass index"},
    {"BNP": "B-type natriuretic peptide"},
    {"BP": "Blood pressure"},
    {"b.p.m.": "Beats per minute"},
    {"BTB": "Bridge to bridge"},
    {"BTC": "Bridge to candidacy"},
    {"BTD": "Bridge to decision"},
    {"BTR": "Bridge to recovery"},
    {"BTT": "Bridge to transplantation"},
    {"CA": "Cardiac amyloidosis (or amyloid cardiomyopathy)"},
    {"CABANA": "Catheter Ablation vs. Anti-arrhythmic drug therapy for Atrial fibrillation (trial)"},
    {"CABG": "Coronary artery bypass graft"},
    {"CAD": "Coronary artery disease"},
    {"CANVAS-R": "CANagliflozin cardioVascular Assessment Study-Renal"},
    {"CARE-HF": "Cardiac Resynchronization in Heart Failure"},
    {"CASTLE-AF": "Catheter Ablation versus Standard conventional Treatment in patients with Left ventricular and Atrial Fibrillation (trial)"},
    {"CCB": "Calcium channel blocker"},
    {"CCS": "Chronic coronary syndrome"},
    {"CHA2DS2-VASc": "Congestive heart failure or left ventricular dysfunction, Hypertension, Age ≥ 75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74, Sex category (female) (score)"},
    {"CHAMPIT": "Acute Coronary syndrome/Hypertension emergency/Arrhythmia/acute Mechanical cause/Pulmonary embolism/Infections/Tamponade"},
    {"CHARM": "Candesartan in Heart Failure-Assessment of Mortality and Morbidity (trial)"},
    {"CHF": "Chronic heart failure"},
    {"CI": "Confidence interval"},
    {"CKD": "Chronic kidney disease"},
    {"CMP": "Cardiomyopathy"},
    {"CMR": "Cardiac magnetic resonance"},
    {"CMV": "Cytomegalovirus"},
    {"COAPT": "Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for HF patients with functional mitral regurgitation (trial)"},
    {"COC": "Cardio-Oncology Council (part of the European Society of Cardiology)"},
    {"COMMANDER-HF": "A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (trial)"},
    {"COMPASS": "Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (trial)"},
    {"COPD": "Chronic obstructive pulmonary disease"},
    {"CORONA": "Controlled Rosuvastatin multiNAtional (trial)"},
    {"COVID-19": "Coronavirus disease 2019"},
    {"CR": "Controlled release"},
    {"CREDENCE": "Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (trial)"},
    {"CRT": "Cardiac resynchronization therapy"},
    {"CRT-D": "Cardiac resynchronization therapy with defibrillator"},
    {"CRT-P": "Cardiac resynchronization therapy pacemaker"},
    {"CSA": "Central sleep apnoea"},
    {"CT": "Computed tomography"},
    {"CTCA": "Computed tomography coronary angiography"},
    {"CV": "Cardiovascular"},
    {"DAPA-HF": "Dapagliflozin And Prevention of Adverse outcomes in Heart Failure (trial)"},
    {"DCM": "Dilated cardiomyopathy"},
    {"DECLARE-TIMI58": "Dapagliflozin Effect on Cardiovascular Events (Thrombolysis in Myocardial Infarction) (trial)"},
    {"DIAMOND": "Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (trial)"},
    {"DIG": "Digitalis Investigation Group (trial)"},
    {"DNA": "Deoxyribonucleic acid"},
    {"DOAC": "Direct-acting oral anticoagulant"},
    {"DPD": "3,3-diphosphono-1,2-propanodicarboxylic acid"},
    {"DPP-4": "Dipeptidyl peptidase-4"},
    {"DSC2": "Desmocollin 2"},
    {"DSG2": "Desmoglein 2"},
    {"DSP": "Desmoplakin"},
    {"DT": "Destination therapy"},
    {"E/e0": "Early filling velocity on transmitral Doppler/early relaxation velocity on tissue Doppler (ratio)"},
    {"EACVI": "European Association of Cardiovascular Imaging (part of the European Society of Cardiology)"},
    {"EAST-AFNET4": "Early Treatment of Atrial Fibrillation for Stroke Prevention Trial 4 (trial)"},
    {"ECG": "Electrocardiogram"},
    {"EchoCRT": "Echocardiography Guided Cardiac Resynchronization Therapy (trial)"},
    {"ECLS": "Extracorporeal life support"},
    {"ECMO": "Extracorporeal membrane oxygenation"},
    {"EF": "Ejection fraction"},
    {"eGFR": "Estimated glomerular filtration rate"},
    {"EHRA": "European Heart Rhythm Association"},
    {"EMA": "European Medicines Agency"},
    {"EMB": "Endomyocardial biopsy"},
    {"EMPA-REG OUTCOME": "Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (trial)"},
    {"EMPEROR-Reduced": "Empagliflozin outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction (trial)"},
    {"EROA": "Effective regurgitant orifice area"},
    {"ESC": "European Society of Cardiology"},
    {"EU": "European Union"},
    {"EuroSCORE II": "European System for Cardiac Operative Risk Evaluation II (score)"},
    {"FDA": "Food and Drug Administration"},
    {"FDG": "Fluorodeoxyglucose"},
    {"FiO2": "Fraction of inspired oxygen"},
    {"FLN": "Filamin"},
    {"FLNC": "Filamin C"},
    {"GGT": "Gamma-glutamyl transferase"},
    {"GISSI-HF": "Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico Heart Failure (trial)"},
    {"GLP-1": "Glucagon-like peptide-1"},
    {"GUIDE-HF": "Hemodynamic-GUIDEd Management of Heart Failure (trial)"},
    {"h": "Hour/hours"},
    {"H2FPEF": "Heavy (BMI > 30 kg/m2), Hypertensive (use of ≥ 2 antihypertensive medications), atrial Fibrillation (paroxysmal or persistent), Pulmonary hypertension (Doppler Echocardiographic estimated Pulmonary Artery Systolic Pressure > 35 mmHg), Elderly (age > 60 years), Filling pressure (Doppler Echocardiographic E/e’ > 9) (score)"},
    {"HbA1c": "Glycated haemoglobin"},
    {"HCM": "Hypertrophic cardiomyopathy"},
    {"HEART": "Heart Failure Revascularisation Trial"},
    {"HER2": "Human epidermal growth factor receptor 2"},
    {"HF": "Heart failure"},
    {"HFA": "Heart Failure Association"},
    {"HFA-PEFF": "Heart Failure Association of ESC diagnostic algorithm, P Initial Workup (Step 1: Pretest Assessment), E-Diagnostic Workup (Step 2: Echocardiographic and Natriuretic Peptides score), F1 Advanced Workup (Step 3: Functional testing in Case of Uncertainty), F2 Aetiological Workup (Step 4: Final Aetiology)"},
    {"HF-MP": "Heart failure management programme"},
    {"HFmrEF": "Heart failure with mildly reduced ejection fraction"},
    {"HFpEF": "Heart failure with preserved ejection fraction"},
    {"HFrEF": "Heart failure with reduced ejection fraction"},
    {"HHV": "Human herpesvirus"},
    {"HIV": "Human immunodeficiency virus"},
    {"HLA-DR": "Human leukocyte antigen-DR isotype"},
    {"HMDP": "Hydroxyl-methylene-diphosphonate"},
    {"HR": "Hazard ratio"},
    {"HT": "Heart transplantation"},
    {"HTM": "Home telemonitoring"},
    {"i.v.": "Intravenous"},
    {"IABP": "Intra-aortic balloon pump"},
    {"ICCU": "Intensive coronary care unit"},
    {"ICD": "Implantable cardioverter-defibrillator"},
    {"ICU": "Intensive care unit"},
    {"IHD": "Ischaemic heart disease"},
    {"INR": "International normalized ratio"},
    {"INTERMACS": "Interagency Registry for Mechanically Assisted Circulatory Support"},
    {"INTrEPID": "Investigation of Non-transplant-Eligible Patients Who Are Inotrope Dependent (trial)"},
    {"IOCM": "Iron overload cardiomyopathy"},
    {"IPD": "Individual patient data"},
    {"I-PRESERVE": "Irbesartan in Patients with Heart Failure and PRESERVED Ejection Fraction (trial)"},
    {"KCNH2": "Potassium voltage-gated channel subfamily H member 2"},
    {"KCNQ1": "Potassium voltage-gated channel subfamily Q member 1"},
    {"LA": "Left atrium/atrial"},
    {"LAE": "Left atrial enlargement"},
    {"LBBB": "Left bundle branch block"},
    {"LDB3": "LIM domain binding 3"},
    {"LFT": "Liver function test"},
    {"LGE": "Late gadolinium enhancement"},
    {"LMNA": "Lamin A/C"},
    {"LMWH": "Low-molecular-weight heparin"},
    {"LUS": "Lung ultrasound"},
    {"LV": "Left ventricular/ventricle"},
    {"LVAD": "Left ventricular assist device"},
    {"LVEDP": "Left ventricular end-diastolic pressure"},
    {"LVEF": "Left ventricular ejection fraction"},
    {"LVESD": "Left ventricular end-systolic diameter"},
    {"LVH": "Left ventricular hypertrophy"},
    {"LVNC": "Left ventricular non-compaction"},
    {"LVOT": "Left ventricular outflow tract"},
    {"LVOTO": "Left ventricular outflow tract obstruction"},
    {"MADIT-CRT": "Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (trial)"},
    {"MADIT-II": "Multicenter Automatic Defibrillator Implantation Trial II (trial)"},
    {"MADIT-RIT": "Multicenter Automatic Defibrillator Implantation Trial Reduce Inappropriate Therapy (trial)"},
    {"MAGGIC": "Meta-Analysis Global Group in Chronic Heart Failure"},
    {"MCS": "Mechanical circulatory support"},
    {"MEK": "Mitogen-activated protein kinase"},
    {"MI": "Myocardial infarction"},
    {"MITRA-FR": "Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation (trial)"},
    {"MMR": "Mismatch repair"},
    {"MR": "Mitral regurgitation"},
    {"MRA": "Mineralocorticoid receptor antagonist"},
    {"MRI": "Magnetic resonance imaging"},
    {"mRNA": "Messenger ribonucleic acid"},
    {"MR-proANP": "Mid-regional pro-atrial natriuretic peptide"},
    {"MT": "Medical therapy"},
    {"MV": "Mitral valve"},
    {"mWHO": "Modified World Health Organization"},
    {"MYPC": "Myosin-binding protein C"},
    {"NICM": "Non-ischaemic cardiomyopathy"},
    {"NKX2-5": "NK2 transcription factor related, locus 5"},
    {"NP": "Natriuretic peptide"},
    {"NSAID": "Non-steroidal anti-inflammatory drug"},
    {"NSVT": "Non-sustained ventricular tachycardia"},
    {"NT-proBNP": "N-terminal pro-B-type natriuretic peptide"},
    {"NYHA": "New York Heart Association"},
    {"o.d": "Omne in die (once daily)"},
    {"OMT": "Optimal medical therapy"},
    {"OSA": "Obstructive sleep apnoea"},
    {"PA": "Pulmonary artery"},
    {"PaO2": "Partial pressure of oxygen"},
    {"PARADIGM-HF": "Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure (trial)"},
    {"pCO2": "Partial pressure of carbon dioxide"},
    {"PCI": "Percutaneous coronary intervention"},
    {"PCR": "Polymerase chain reaction"},
    {"PCWP": "Pulmonary capillary wedge pressure"},
    {"PEP-CHF": "Perindopril in Elderly People with Chronic Heart Failure (trial)"},
    {"PET": "Positron emission tomography"},
    {"PKP2": "Plakophilin 2"},
    {"PLN": "Phospholamban"},
    {"PPCM": "Peripartum cardiomyopathy"},
    {"PREVEND": "Prevention of Renal and Vascular End-stage Disease (trial)"},
    {"PV": "Pulmonary vein"},
    {"PVC": "Premature ventricular contraction"},
    {"PVI": "Pulmonary vein isolation"},
    {"pVO2": "Peak exercise oxygen consumption"},
    {"QI": "Quality indicator"},
    {"QOL": "Quality of life"},
    {"QRS": "Q, R, and S waves of an ECG"},
    {"RAAS": "Renin-angiotensin-aldosterone system"},
    {"RACEII": "Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison between Lenient versus Strict Rate Control II (trial)"},
    {"RAFT": "Resynchronization/Defibrillation for Ambulatory Heart Failure Trial (trial)"},
    {"RASi": "Renin-angiotensin system inhibitor"},
    {"RATE-AF": "Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (trial)"},
    {"RBM20": "Ribonucleic acid binding motif 20"},
    {"RCT": "Randomized controlled trial"},
    {"REMATCH": "Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (trial)"},
    {"REVERSE": "Resynchronization REVErses Remodeling in Systolic left Ventricular dysfunction (trial)"},
    {"REVIVED": "REVascularization for Ischaemic VEntricular Dysfunction (trial)"},
    {"RNA": "Ribonucleic acid"},
    {"RRT": "Renal replacement therapy"},
    {"RV": "Right ventricular/ventricle"},
    {"RVAD": "Right ventricular assist device"},
    {"RVEDP": "Right ventricular end-diastolic pressure"},
    {"SARS-CoV-2": "Severe acute respiratory syndrome coronavirus 2"},
    {"SAVR": "Surgical aortic valve replacement"},
    {"SBP": "Systolic blood pressure"},
    {"SCN5a": "Sodium channel alpha subunit 5"},
    {"SCORED": "Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (trial)"},
    {"SENIORS": "Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalizations in Seniors with Heart Failure (trial)"},
    {"SERVE-HF": "Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients with Heart Failure (trial)"},
    {"SGLT2": "Sodium-glucose co-transporter 2"},
    {"S-ICD": "Subcutaneous implantable cardioverter defibrillator"},
    {"SMR": "Secondary mitral regurgitation"},
    {"SPECT": "Single-photon emission computed tomography"},
    {"SpO2": "Transcutaneous oxygen saturation"},
    {"SR": "Sinus rhythm"},
    {"STEMI": "ST-elevation myocardial infarction"},
    {"STICH": "Surgical Treatment for Ischemic Heart Failure (trial)"},
    {"STICHES": "Extended follow-up of patients from the STICH trial"},
    {"STS-PROM": "Society of Thoracic Surgeons Predicted Risk of Mortality"},
    {"SZC": "Sodium zirconium cyclosilicate"},
    {"T2DM": "Type 2 diabetes mellitus"},
    {"TAVI": "Transcatheter aortic valve implantation"},
    {"TFT": "Thyroid function test"},
    {"t.i.d.": "Ter in die (three times a day)"},
    {"TKI": "Tyrosine kinase inhibitor"},
    {"TMEM43": "Transmembrane protein 43"},
    {"TNNT": "Troponin-T"},
    {"TR": "Tricuspid regurgitation"},
    {"TRPM4": "Transient receptor potential cation channel subfamily M member 4"},
    {"TSAT": "Transferrin saturation"},
    {"TSH": "Thyroid-stimulating hormone"},
    {"TTN": "Titin"},
    {"TTR": "Transthyretin"},
    {"UK": "United Kingdom"},
    {"US": "United States"},
    {"VAD": "Ventricular assist device"},
    {"Val-HeFT": "Valsartan Heart Failure Trial (trial)"},
    {"VEGF": "Vascular endothelial growth factor"},
    {"VERTIS-CV": "Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease (trial)"},
    {"VEST": "Vest Prevention of Early Sudden Death Trial (trial)"},
    {"VKA": "Vitamin K antagonist"},
    {"VO2": "Oxygen consumption"},
    {"VPB": "Ventricular premature beat"},
    {"vs.": "Versus"},
    {"VV interval": "Interventricular delay interval"},
    {"WARCEF": "Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (trial)"},
    {"wtTTR-CA": "Wild-type transthyretin cardiac amyloidosis"},
    {"XL": "Extended release"}
]
